Often, pharmaceutical companies avoid new laboratory testing methodologies preferring to stick to established procedures for drug development so as to avoid any potential regulatory ambiguity. This tendency to avoid new methodologies and regulatory scrutiny sometimes leads to slower progress, higher costs and lower probability of new product approvals. Furthermore, some pharmaceutical firms severely restrict academic research-based modifications to established laboratory testing procedures in drug development because of their concern over triggering costly adjustments to the established regulatory framework.
KFI is a veterinary contract research organization (CRO) that specializes in in-vivo GLP/GCP studies in dogs, cats and horses. We have a reputation for satisfying our clients by providing high quality services in a timely manner with the utmost attention to the latest scientific research and regulatory standards.
Ultratech Has Gained The Reputation And Capabilities For Assisting Manufacturers And Designers In Obtaining The Appropriate Regulatory Product Compliance For Global Markets. Ultratechs Recognized Expertise Is In The Areas Of Product Modification And Re-De